Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Receivables (2016 - 2026)

Gyre Therapeutics has reported Receivables over the past 16 years, most recently at $31.3 million for Q4 2025.

  • Quarterly Receivables rose 57.97% to $31.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.3 million through Dec 2025, up 57.97% year-over-year, with the annual reading at $31.3 million for FY2025, 57.97% up from the prior year.
  • Receivables was $31.3 million for Q4 2025 at Gyre Therapeutics, up from $26.8 million in the prior quarter.
  • Over five years, Receivables peaked at $31.3 million in Q4 2025 and troughed at $564000.0 in Q1 2022.
  • The 5-year median for Receivables is $16.0 million (2023), against an average of $13.1 million.
  • Year-over-year, Receivables plummeted 45.13% in 2021 and then surged 842.57% in 2022.
  • A 5-year view of Receivables shows it stood at $1.8 million in 2021, then surged by 842.57% to $17.1 million in 2022, then fell by 6.61% to $16.0 million in 2023, then grew by 23.84% to $19.8 million in 2024, then surged by 57.97% to $31.3 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Receivables are $31.3 million (Q4 2025), $26.8 million (Q3 2025), and $25.1 million (Q2 2025).